Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Schrödinger, Inc.
Schrödinger, Inc. News
Schrödinger, Inc. Quantitative Score
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Schrödinger, Inc. Financials
Table Compare
Compare SDGR metrics with: | |||
|---|---|---|---|
Earnings & Growth | SDGR | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SDGR | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SDGR | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SDGR | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Schrödinger, Inc. Income
Schrödinger, Inc. Balance Sheet
Schrödinger, Inc. Cash Flow
Schrödinger, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Schrödinger, Inc. Executives
| Name | Role |
|---|---|
| Dr. Ramy Farid Ph.D. | Chief Executive Officer, President & Director |
| Dr. Geoffrey Craig Porges MBBS | Executive Vice President & Chief Financial Officer |
| Dr. Karen Akinsanya Ph.D. | President of Research & Development Therapeutics |
| Mr. Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software |
| Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Ramy Farid Ph.D. | Chief Executive Officer, President & Director | 1965 | 1.24M | |
| Dr. Geoffrey Craig Porges MBBS | Executive Vice President & Chief Financial Officer | 1.04M | ||
| Dr. Karen Akinsanya Ph.D. | President of Research & Development Therapeutics | 1968 | 931.41K | |
| Mr. Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software | Male | 1984 | 736.84K |
| Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling R&D | 1982 | 736.84K |
Schrödinger, Inc. Insider Trades
| Date | 18 Jun |
| Name | Chodakewitz Jeffrey |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5997 |
| Date | 18 Jun |
| Name | Chodakewitz Jeffrey |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 9341 |
| Date | 18 Jun |
| Name | Sender Gary |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5997 |
| Date | 18 Jun |
| Name | Sender Gary |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 9341 |
| Date | 18 Jun |
| Name | Lynton Michael |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5997 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 18 Jun | Chodakewitz Jeffrey | Director | Acquired | A-Award | 5997 |
| 18 Jun | Chodakewitz Jeffrey | Director | Acquired | A-Award | 9341 |
| 18 Jun | Sender Gary | Director | Acquired | A-Award | 5997 |
| 18 Jun | Sender Gary | Director | Acquired | A-Award | 9341 |
| 18 Jun | Lynton Michael | Director | Acquired | A-Award | 5997 |